Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke

The randomized controlled trial (RCT) of GDLM for the treatment of AIS was published in JAMA Network Open, titled "Efficacy and Safety of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke: A Randomized Clinical Trial." This study provided valuable insights into the efficacy and safety of GDLM in improving functional recovery for patients with AIS. However, the generalizability of these findings to real-world medical settings remains unclear, as the trial was conducted under controlled conditions that may not fully reflect routine clinical practice. To address this gap, we will conduct this study to further explore the effectiveness of GDLM in a real medical environment. Using routine clinical care data for real-world evidence, we aim to investigate the treatment's impact on a broader and more diverse patient population. This approach will allow us to better understand the practical application of GDLM in everyday clinical settings, including its potential benefits and challenges when used outside the confines of a RCT.

• Proportion of patients with an mRS score of 2 or less [Срок оценки: on day 90 after onset]
• Distribution of mRS scores [Срок оценки: on day 90 after onset]
• Incidence of new-onset stroke events (ischemic stroke or hemorrhagic stroke) [Срок оценки: within 90 days after onset]
• Mortality rate [Срок оценки: within 90 days after onset]
• Incidence of severe or moderate bleeding events (as defined by GUSTO criteria) [Срок оценки: during hospital stay (up to 14 days)]